Intermittent vs continuous docetaxel therapy in patients with metastatic castration‐resistant prostate cancer – a phase III study (PRINCE)

Abstract

Intermittent docetaxel chemotherapy was non-inferior to continuous therapy for 1-year survival; non-inferiority in regard to OS was not reached.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

“…Различия в ВБП и среднее время до прогрессирования были незначимы. Средний интер-вал между введениями в группе интермиттирующей терапии составил 110 сут (13-486 сут), или 38 % от об-щей длительности лечения, однако это не привело к улучшению профиля токсичности [59].…”

Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases

“…8,[14][15][16] However, theoretically, continuous therapy may have better results compared to intermittent therapy. 17 A Phase III clinical trial (PRINCE) 18 compared continuous docetaxel therapy with intermittent docetaxel therapy in patients with mCRPC. Although the one-year survival showed that intermittent docetaxel therapy was not inferior to continuous docetaxel therapy, the median OS of continuous docetaxel was better than that of intermittent docetaxel (19.3 mouths vs 18.3mouths).…”

Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review

“…Patients were randomized to receive up to 3 or 4 cycles of chemotherapy and then restarted upon disease progression (clinical [RE-CIST] or biochemical progression [PSA > 4ng/mL with > 50% of baseline]). The study concluded that there was no difference in terms of OS (18.3 vs. 19.3 months in the continuous arm; HR 1.14, 95% CI 0.75-1.72, p = 0.535), PFS (10 vs. 5.4 months; HR 0.69, 95% CI 0.42-1.04, p = 0.077), or safety profile between both regimens (grade 3-4 anemia in 1.3 vs. 3.8% and neutropenia 8.9% in both groups) [32].…”

“…The most common grade 3-4 adverse events were pain (14.7%), leukocytopenia (6.7%), and nail disorders (5.3%) [31]. Last, a prospective non-inferiority phase III trial (PRINCE) compared the intermittent to the continuous administration of docetaxel (75 mg/m 2 every 3 weeks or 35 mg/m 2 weekly for 3 weeks on a 4-week schedule) in 187 mCRPC patients [32]. Patients were randomized to receive up to 3 or 4 cycles of chemotherapy and then restarted upon disease progression (clinical [RE-CIST] or biochemical progression [PSA > 4ng/mL with > 50% of baseline]).…”